This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BioLineRx: Tuesday's Hot Hep C Drug Stock

Stocks in this article: BLRX IDIX ACHN GILD BMY JNJ INHX

Updated with current stock price.

JERUSALEM ( TheStreet) -- A tiny Israeli drug maker that few investors have ever heard of announces a licensing deal Tuesday with a French company similarly unknown, but the deal involves an oral hepatitis C pill so shares of the Israeli company doubling in value.

Just another day inside Wall Street's ever-expanding hepatitis C bubble.

BioLineRx (BLRX) shares are up $3.45, or 104%, to $6.75 after announcing the licensing deal for hepatitis C drug BL-8020, developed by the privately held French firm Genoscience. Almost 5 million BioLineRx shares have traded hands Tuesday already, blowing away the stock's average daily volume of a miniscule 3,600 shares.

Terms of the BioLineRx-Genoscience deal were not disclosed.

Little is known about BL-8020, which is still in preclinical testing, meaning the drug hasn't yet been studied in humans. But with all of Wall Street looking for the next hot hepatitis C drug stock, the mere mention of a potentially new oral therapy for the viral liver disease was enough to make BioLineRx the hot speculative biotech trade for Tuesday morning, fueled by a robust Twitter buzz.

BL-8020 may belong to the class of direct-acting antiviral agents known as protease inhibitors, according to an overview of the drug discovery research in hepatitis C noted on Genoscience's web site. Both Vertex Pharmaceuticals' (VRTX) Incivek and Merck's (MRK) Victrelis are both protease inhibitors and most of the other big Hep C players, including Johnson & Johnson (JNJ), Gilead Sciences (GILD), Abbott (ABT) and Bristol-Myers Squibb (BMY), already have protease inhibitors in development.

Achillion Pharmaceuticals (ACHN) is also developing a protease inhibitor and has been seeking a partner for the drug or a suitor to buy the entire company.

If you missed Tuesday's BioLineRx move, the next Hep C-related stock action could come early next month when Bristol-Myers Squibb is expected to close out its $2.5 billion tender offer for Inhibitex (INHX). Around the same time, Inhibitex (or Bristol) is expected to announce early data from a phase II study of INX-189, the company's lead hepatitis C drug candidate.

Investors are also waiting for Idenix Pharmaceuticals (IDIX) to announce the FDA's decision on lifting a clinical hold on IDX184, which will allow the company to push the hepatitis C drug into additional clinical studies. Or perhaps, clear the way for Idenix to be acquired.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs